1. Home
  2. IGIC vs DBVT Comparison

IGIC vs DBVT Comparison

Compare IGIC & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo International General Insurance Holdings Ltd.

IGIC

International General Insurance Holdings Ltd.

HOLD

Current Price

$28.69

Market Cap

1.1B

Sector

Finance

ML Signal

HOLD

DBVT

DBV Technologies S.A.

HOLD

Current Price

$13.68

Market Cap

948.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IGIC
DBVT
Founded
2001
2002
Country
Jordan
France
Employees
N/A
90
Industry
Property-Casualty Insurers
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
948.8M
IPO Year
2019
2014

Fundamental Metrics

Financial Performance
Metric
IGIC
DBVT
Price
$28.69
$13.68
Analyst Decision
Buy
Buy
Analyst Count
1
7
Target Price
$28.00
$32.04
AVG Volume (30 Days)
89.1K
275.2K
Earning Date
05-05-2026
05-12-2026
Dividend Yield
5.25%
N/A
EPS Growth
N/A
10.26
EPS
N/A
N/A
Revenue
N/A
$5,636,000.00
Revenue This Year
$0.13
$35.04
Revenue Next Year
$2.54
$2,360.78
P/E Ratio
$9.05
N/A
Revenue Growth
N/A
35.77
52 Week Low
$20.82
$8.51
52 Week High
$28.84
$26.19

Technical Indicators

Market Signals
Indicator
IGIC
DBVT
Relative Strength Index (RSI) 63.36 32.26
Support Level $24.51 $12.63
Resistance Level $28.84 $14.68
Average True Range (ATR) 0.67 0.87
MACD -0.01 -0.17
Stochastic Oscillator 93.10 11.88

Price Performance

Historical Comparison
IGIC
DBVT

About IGIC International General Insurance Holdings Ltd.

International General Insurance Holdings Ltd is an international specialty insurance and reinsurance group. It underwrites a diversified portfolio of specialty risks including energy, property, construction and engineering, ports and terminals, general aviation, political violence, professional lines, financial institutions, marine, contingency and treaty reinsurance. The company's operating segments include Specialty Longtail, Specialty Short tail and Reinsurance. The majority of revenue is derived from the Specialty Short-tail segment, which comprises business lines with underwriting risks assumed in the form of property and specialty lines insurance and of short-term nature with respect to related claims.

About DBVT DBV Technologies S.A.

DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.

Share on Social Networks: